Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.

Zi-Xian WangHao-Xiang WuLi XieWu-Hao LinFei LiangJin LiZhi-Min YangRui-Hua Xu

Published in: Journal for immunotherapy of cancer (2021)

mPFS outperformed PFS as the surrogate endpoint for OS in ICI trials. mPFS is worthy of further investigation as a secondary endpoint in future ICI trials.

Keyphrases

free survival
palliative care